Form 144 - Report of proposed sale of securities:
SEC Accession No. 0001140361-24-041079
Filing Date
2024-09-13
Accepted
2024-09-13 17:04:54
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html 144  
1 primary_doc.xml 144 4213
  Complete submission text file 0001140361-24-041079.txt   6080
Mailing Address 3160 PORTER DR. SUITE 250 PALO ALTO CA 94304
Business Address 3160 PORTER DR. SUITE 250 PALO ALTO CA 94304 (650) 391-9740
BridgeBio Pharma, Inc. (Subject) CIK: 0001743881 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 144 | Act: 33 | File No.: 001-38959 | Film No.: 241298512
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O KOHLBERG KRAVIS ROBERTS & CO. L.P. 9 WEST 57TH STREET, SUITE 4200 NEW YORK NY 10019
Business Address C/O KOHLBERG KRAVIS ROBERTS & CO. L.P. 9 WEST 57TH STREET, SUITE 4200 NEW YORK NY 10019 (212) 750-8300
KKR Genetic Disorder L.P. (Reporting) CIK: 0001780408 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 144